Tirzepatide (Mounjaro)
Tirzepatide
A dual GIP/GLP-1 receptor agonist (Mounjaro) approved for type 2 diabetes with superior glycemic control and weight loss. Now also approved as Zepbound for obesity.
Typical Cost
$1000-1600/month (brand), $200-500 (compounded)
Status
Research
Peptide Profile
Tirzepatide (Mounjaro)
Mechanism of Action
Activates both GIP and GLP-1 receptors, providing enhanced insulin secretion, glucagon suppression, appetite reduction, and energy expenditure. The dual mechanism produces superior metabolic effects compared to GLP-1 alone.
Common Dosages
subcutaneous
2.5-15mg
Weekly · Ongoing
Benefits
Superior HbA1c reduction up to 2.4%
Greatest weight loss 20.9%
Improved lipid profiles
Enhanced satiety
Weekly dosing convenience
Side Effects
Nausea
Vomiting
Diarrhea
Constipation
Injection site reactions
More GI effects initially
Key Research
SURMOUNT-1 - Tirzepatide for obesity
Unprecedented 20.9% weight loss at 72 weeks with 15mg dose
SURPASS program - Glycemic control
Superior HbA1c reduction compared to all other diabetes medications
Regulatory Status
FDA-approved as Mounjaro for diabetes and Zepbound for weight management. Available by prescription.
Contraindications
- ⚠Medullary thyroid carcinoma history
- ⚠MEN2 syndrome
- ⚠Pregnancy/breastfeeding
- ⚠History of pancreatitis
SeraVia Gut+ Balance is particularly valuable for tirzepatide users managing enhanced GI side effects during titration.
Learn More →Find peptide providers
Search 18,000+ clinics offering peptide therapy alongside GLP-1 medications.
Search Providers →Disclaimer: This information is for educational and research purposes only. Peptides described here may not be FDA-approved for human use. Always consult a qualified healthcare provider before using any peptide product. GLP1Search does not sell peptides.